How to be different in in vivo Car-T
After Astra's EsoBiotec takeover the battle for uniqueness begins.
Astra gives in vivo Car-T its biggest endorsement
The company buys Belgium’s EsoBiotec for $425m.
Arvinas’s degrader disappoints
The Pfizer-partnered vepdegestrant shows a benefit in ESR1 mutants, but not in all-comers.
Imfinzi puts its flag on the Matterhorn
A hit on EFS will challenge regulators, and points to Merck's design blunder in Keynote-585.
T-cell engagement with a difference
In8bio joins Lava in going beyond basic CD3-based T-cell engager MAbs.
GSK and Hansoh press on despite Pfizer’s exit
A Chinese phase 3 trial of the partners’ B7-H4-targeting ADC has just begun.
